About Us


Drug Delivery


Wound Care


TET Systems




A Special Initiative  

The company is seeking individual or group investors who are interested in a unique opportunity to improve the treatment of a disease that kills approximately one million children under the age of five annually in under-developed countries. Malaria is a mosquito spread disease that is readily cured if treated early. Unfortunately, a lack of infrastructure often leads to children not receiving care until it is too late. Researchers at the Massachusetts General Hospital (MGH) in Boston are conducting a clinical trial using an inhaled gas (nitric oxide) that has been shown to significantly prolong survival in severe malaria, making treatment possible in cases that would otherwise be hopeless. Nitric oxide gas for medical use is too expensive for widespread use, however, and Whalen Biomedical is developing a device to generate the gas from room air, making it available in unlimited quantity and at low cost.

The company has just received a Phase I SBIR from the National Institute of Allergy and Infectious Diseases (NIAID) to develop this device and evaluate it in the treatment of malaria. We would like to accelerate this work and contribute to lessening the impact of malaria on children in under-developed countries.

Please contact us for more information.


Powered by